Bay Area's Tricia Closes $57.5M Series D, Pushes Into Phase III Trial Post author:Sam Post published:November 7, 2017 Post category:BioPharma Proceeds will be used to complete the ongoing pivotal TRCA-301 Phase 3 clinical trial of TRC101. Source: BioSpace You Might Also Like Effective Today: Cancer Biotech ImMAGE Shutters Operations August 31, 2017 Stanford, NCI Researchers Discover New CAR-T Target With Early Study Data November 20, 2017 GTX Corp Provides Corporate Update And Reports Second Quarter 2017 Financial Results August 13, 2017